OBJECTIVE: Combining the therapeutic and diagnostic properties of targeted antibodies may improve clinical assessment of disease with limited added toxicity during treatment. METHODS: Mice (n = 10) were xenografted with SCC-1 tumor cells and then treated with radiation, cisplatin and cetuximab. Brightfield and fluorescent imaging was performed after systemically injecting fluorescently labeled cetuximab prior to treatment and at six or ten weeks after initiation of treatment. The relative fluorescence intensity was determined for each image. RESULTS: The tumor luminosity measured before (week 0), during (week 6) and after treatment (week 10) did not significantly change. Actual tumor measurement corresponded to fluorescent measurements of tumors both before treatment and after treatment. Complete response to therapy occurred in one animal, where resolution of the tumor correlated with loss of fluorescent activity. CONCLUSIONS: This preclinical data suggests combining the diagnostic and therapeutic properties of cetuximab may be clinically useful.
OBJECTIVE: Combining the therapeutic and diagnostic properties of targeted antibodies may improve clinical assessment of disease with limited added toxicity during treatment. METHODS:Mice (n = 10) were xenografted with SCC-1tumor cells and then treated with radiation, cisplatin and cetuximab. Brightfield and fluorescent imaging was performed after systemically injecting fluorescently labeled cetuximab prior to treatment and at six or ten weeks after initiation of treatment. The relative fluorescence intensity was determined for each image. RESULTS: The tumor luminosity measured before (week 0), during (week 6) and after treatment (week 10) did not significantly change. Actual tumor measurement corresponded to fluorescent measurements of tumors both before treatment and after treatment. Complete response to therapy occurred in one animal, where resolution of the tumor correlated with loss of fluorescent activity. CONCLUSIONS: This preclinical data suggests combining the diagnostic and therapeutic properties of cetuximab may be clinically useful.
Authors: Anna G Sorace; Melissa Korb; Jason M Warram; Heidi Umphrey; Kurt R Zinn; Eben Rosenthal; Kenneth Hoyt Journal: Ultrasound Med Biol Date: 2014-01-10 Impact factor: 2.998
Authors: Kristine E Day; Lauren N Beck; C Hope Heath; Conway C Huang; Kurt R Zinn; Eben L Rosenthal Journal: Cancer Biol Ther Date: 2013-01-08 Impact factor: 4.742
Authors: Kristine E Day; Lauren N Beck; Nicholas L Deep; Joy Kovar; Kurt R Zinn; Eben L Rosenthal Journal: Laryngoscope Date: 2013-04-24 Impact factor: 3.325
Authors: Melissa L Korb; Yolanda E Hartman; Joy Kovar; Kurt R Zinn; Kirby I Bland; Eben L Rosenthal Journal: J Surg Res Date: 2013-11-22 Impact factor: 2.192
Authors: Kurt R Zinn; Melissa Korb; Sharon Samuel; Jason M Warram; David Dion; Cheryl Killingsworth; Jinda Fan; Trenton Schoeb; Theresa V Strong; Eben L Rosenthal Journal: Mol Imaging Biol Date: 2015-02 Impact factor: 3.488
Authors: J Robert Newman; John P Gleysteen; Christopher F Barañano; Jennifer R Bremser; Wenyue Zhang; Kurt R Zinn; Eben L Rosenthal Journal: Cancer Biol Ther Date: 2008-04-14 Impact factor: 4.742